TELA Bio (TELA) Q2 FY26 earnings call

TELA Bio reported a revenue miss in Q2 FY26, primarily driven by underperformance in its OviTex PRS portfolio and longer-than-anticipated sales force productivity ramps. The company withdrew its full-year guidance and announced plans to reduce its cost structure, while maintaining optimism for a second-half recovery in PRS and continued international growth. Leadership changes were also highlighted, with a new CEO focused on operational excellence and financial transformation.